High-dose chemo followed by a stem cell transplant may be another option. Some doctors suggest maintenance chemo for up to 2 years after the initial treatment to reduce the risk of recurrence. Because of the risk of spread to the brain and spinal cord, a chemo drug such as methotrexate is also given into the spinal fluid. These can include cyclophosphamide, doxorubicin (Adriamycin), vincristine, L-asparaginase, methotrexate, prednisone, and, sometimes, cytarabine (ara-C). Regardless of whether it’s labeled as a lymphoma or a leukemia, this is a fast-growing disease that’s treated with intensive chemotherapy (chemo), when possible.Ĭombinations of many drugs are used. (Leukemias have more bone marrow involvement.) This disease can occur in both children and adults, and it can be considered either a lymphoma or a type of acute lymphoblastic leukemia (ALL), depending on how much of the bone marrow is involved. There are many different types of T-cell lymphomas, and treatment can vary based on which type you have. It is best to be aware that a correction is very likely, so consider the timing carefully to avoid getting caught in the landslide.Non-Hodgkin lymphoma (NHL) is generally divided into main 2 types, based on whether it starts in B lymphocytes (B cells) or T lymphocytes (T cells). (OTCMKTS: ECOB), which grew more than four times in a single day, but then immediately started to step downward, practically wiping out all the gains in a long string of days in the red.įor now, TCEL has very little to offer, and the best day may already be just a note of the past. Investors’ forums compare TCEL to the run of Eco Building Products, Inc. In the case of TCEL, there is no mention of similar promises, and the next few days will show if this is a fluke. This has been beneficial for EAPH, which managed to preserve at least a piece of the gains, as it shot upward from $0.0025 to a peak at eight cents, and is still hanging on at $0.03. Many stem cell researchers, such as Easton Pharmaceuticals, Inc.(OTCMKTS: EAPH) turned from stem cells to medical cannabis. TCEL is thus not the classical pharmaceutical or stem cell company, as such tickers choose a different path in recent months. BRGO was slashed in half in recent days, from its peak at $0.0015 to $0.0007. BRGO is known for its paradoxical position- a solid company, potentially generating strong revenues, but with a rock-bottom stock price, often going down to triple-zero levels. (OTCMKTS: BRGO), and until 2011 the pink sheet was the original diamonds and jewelry company. In the past, TCEL in fact spun off Bergio International, Inc. Also, the company claims that it is a holding interested in purchasing already developed businesses. It claims that it is researching a restorative auto-transplant of cells, and its therapy may emerge soon as a valid therapeutic modality. This also means that TCEL is underpriced enough, and a concerted buying effort could secure enough of a squeeze to bring the price upward as well as it did.Īlso, it is hard to tell what TCEL is up to. ![]() $52,000 net loss for the September 30th quarter of 2013Īs it is easily seen, TCEL hardly even justifies the $3 million current market cap, though it holds a still reasonable number of shares, 93 million.Nothing in the past years indicates that TCEL is having any progress, and its financials reveal: ![]() What is strange is that there are hardly updates from TCEL, the financial reports are quite old, and the company only retells its old stories of successful stem cell therapies. All of this makes us suspect concerted buying efforts, which sent the ticker up by more than 459% on Tuesday, reaching $0.033, on dollar volumes above $2.82 million. The stem cell company gained instantly from double-zero positions into penny levels, all of this without a boost from new emails or PR materials. (OTCMKTS: TCEL), two record days of buying may look good- but they also look worrying.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |